• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • HIV/AIDS
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • HIV/AIDS
    • View Item
    Apr 22, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    120111_Lee_Review-of-the-safet ...
    Size:
    189.6Kb
    Format:
    PDF
    Description:
    Main article
    Download
    Authors
    Lee, Janice Soo Fern
    Calmy, Alexandra
    Andrieux-Meyer, Isabelle
    Ford, Nathan
    Affiliation
    1Médecins Sans Frontières; HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa
    Issue Date
    2012-01-11
    
    Metadata
    Show full item record
    Journal
    HIV/AIDS - Research and Palliative Care
    Abstract
    Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.
    Publisher
    DovePress
    URI
    http://hdl.handle.net/10144/220338
    DOI
    10.2147/HIV.S20993
    PubMed ID
    22347806
    Additional Links
    http://www.dovepress.com/review-of-the-safety-efficacy-and-pharmacokinetics-of-elvitegravir-wit-peer-reviewed-article-HIV
    Type
    Article
    Language
    en
    ISSN
    1179-1373
    ae974a485f413a2113503eed53cd6c53
    10.2147/HIV.S20993
    Scopus Count
    Collections
    HIV/AIDS

    entitlement

    Related articles

    • Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    • Authors: Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL, Study 145 Team.
    • Issue date: 2012 Jan
    • Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
    • Authors: Ramanathan S, Mathias AA, German P, Kearney BP
    • Issue date: 2011 Apr
    • Integrase inhibitors: a novel class of antiretroviral agents.
    • Authors: Schafer JJ, Squires KE
    • Issue date: 2010 Jan
    • Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    • Authors: Cvetkovic RS, Goa KL
    • Issue date: 2003
    • Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
    • Authors: Taiwo B, Murphy RL, Katlama C
    • Issue date: 2010 Sep 10
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.